Blockchain Registration Transaction Record

Clene Announces Q1 2025 Financial Results and Progress on CNM-Au8 Program for ALS and MS

Clene announces first quarter 2025 financial results and updates on CNM-Au8 program for ALS and MS. Progress towards potential FDA approval and positive clinical trial results signify a significant step forward in neurodegenerative disease research.

Clene Announces Q1 2025 Financial Results and Progress on CNM-Au8 Program for ALS and MS

This news matters as Clene's advancements in developing therapies for neurodegenerative diseases like ALS and MS could potentially lead to improved treatment options for patients. The company's progress towards potential FDA approval and positive clinical trial results signify a significant step forward in the field of neurodegenerative disease research.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x1d4e99b1712e6259caaf159938baf0febc7599df08142586c5d87de9230c875f
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintfineticz-bfeac99f67382a02dea42e0d535e7e07